In this proposal,the investigators will examine whether the selectivity of eplerenone for the
MR will translate into a better glucose and metabolic profile compare to spironolactone in
patients with HF with glucose intolerance or type 2 diabetes. In addition, the investigators
will also compare the impact of these two agents on changes of concentrations of established
prognostic biomarkers of neurohormonal activation and extracellular matrix turnover.